WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

D DERMATOLOGICALS

Most of the drugs in this group are preparations for topical use. Some few preparations for systemic use with clear dermatological applications, e.g. griseofulvin (antimycotic), retinoids (for treatment of acne) and psoralens and retinoids (for treatment of psoriasis) are classified in this group.

Only oral preparations in ATC group D are given DDDs. Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease. Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.


D05 ANTIPSORIATICS
D05B ANTIPSORIATICS FOR SYSTEMIC USE

This group comprises drugs for systemic use against psoriasis. Antineoplastic agents, sometimes used in severe psoriasis, are classified in group L - Antineoplastic and immunomodulating agents.

Agents with immunosuppressant properties indicated for treatment of psoriasis are classified in L04 - Immunosuppressants.


D05BA Psoralens for systemic use

The DDDs for psoralens for systemic use are based on the combined treatment with drug and UV-A irradiation.

D05BB Retinoids for treatment of psoriasis

Retinoids for the treatment of acne are classified in D10BA.

Alitretinoin used for hand eczema is classified in D11A.

D05BX Other antipsoriatics for systemic use

Alefacept and efalizumab are classified in L04AA.

Dimethyl fumarate indicated for plaque psoriasis or multiple sclerosis is classified in L04AX.

Last updated: 2018-12-13